skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Tertomotide (Code C62756)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Tertomotide

Definition: A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.

Label: Tertomotide

NCI Thesaurus Code: C62756 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831942  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
GV-1001
GV1001
GV 1001
Human Telomerase Reverse Transcriptase (EC 2.7.7.49)-(611-626)-Peptide (Telomerase Catalytic Subunit Fragment)
PrimoVax
Tertomotide
TERTOMOTIDE

External Source Codes: 
FDA UNII Code 55R7RG342O
PDQ Closed Trial Search ID 502114
PDQ Open Trial Search ID 502114 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831942

Other Properties:
     Name Value (qualifiers indented underneath)
code C62756
Contributing_Source FDA
Legacy_Concept_Name GV1001
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62756

Mainbox Bottom